Capmatinib’s mechanism of action

Capmatinib is an antineoplastic drug indicated for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have mutations that cause mesenchymal epithelial transition (MET) exon 14 skipping . Capmatinib(Capmatinib)The most common adverse reactions (≥ 20%) are edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite.

Capmatinib(Capmatinib) is a kinase inhibitor that targets MET, including mutant variants resulting from exon 14 skipping. METSkipping of exon 14 causes the protein to lose regulatory domains, thereby reducing its negative regulatory effect and resulting in increased downstream MET signaling. At clinically achievable concentrations, capmatinib inhibits the growth of cancer cells driven by mutant MET variants lacking exon 14 Pan>METexon14skipped orMETmutated human lung tumors showed antitumor activity in murine tumor xenograft models. Capmatinibinhibits METphosphorylation triggered by hepatocyte growth factor binding or METamplification, as well as MET-mediated phosphorylation of downstream signaling proteins and MET-dependent cancer cell proliferation and survival. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0